Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized study of vinflunine + gemcitabine versus gemcitabine + carboplatin in cisplatin-ineligible advanced or metastatic urothelial carcinoma
2014-005396-82Phase 3Completed
- Sponsor
- Pierre Fabre Laboratories
- Start
- Jul 2015
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of vinflunine, gemcitabine, carboplatin in transitional cell carcinoma (TCC), sponsored by Pierre Fabre Laboratories. Started Jul 2015; status: completed.
02
Drugs
vinfluninegemcitabinecarboplatin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2014-005396-82.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005396-82.